Clinical trial · Interventional
Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer
Efficacy and Safety of Acupuncture for Relieving Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Acupuncture may help relieve joint stiffness related to aromatase inhibitors in patients with early-stage breast cancer. PURPOSE: This single arm clinical study aims to evaluate how well acupuncture as a non-pharmacological treatment, works in treating patients with joint stiffness related to aromatase inhibitors (AIs) in patients with early-stage breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Stiffness of Hand, Not Elsewhere Classified | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with stiffness of joint receive acupuncture therapy
- description
- This is a single arm study. All the enrolled patients will receive acupuncture twice weekly for 6 weeks then once weekly for another 6 weeks.
- interventionNames
- Device: Acupuncture
Primary outcomes (1)
- measure
- The change in stiffness score as measured by the Western Ontario and McMasters Universities Osteoarthritis (WOMAC)
- timeFrame
- 6 weeks
- description
- The change in stiffness score as measured by the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) at the end of week 6 of intervention compared to that at baseline.
Secondary outcomes (1)
- measure
- The change in stiffness score as measured by the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. History of stage I-III breast cancer and free of disease by clinical examination 2. Postmenopausal or premenopausal with ovarian suppression 3. Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment 4. With joint stiffness attributed to the use of aromatase inhibitors 5. Having had joint stiffness for at least 1 months 6. Having had at least 15 days with stiffness in the preceding 30 days Exclusion Criteria: 1. Women with recurrent or metastatic breast cancer 2. Women having finished chemotherapy or radiation therapy less than 1 months prior to enrollment 3. Women with history of bleeding disorder 4. Women with joint stiffness attributed to inflammatory arthritis, such as rheumatoid arthritis, spondy loarthritis and osteoarthritis 5. Women having joint stiffness prior to AI treatment 6. Women that have received treatment of any kind for joint stiffness within the last 3 months 7. Women that have previously received the acupuncture treatment before for any reason
References
Publications (0)
Data not yet available